Cargando…

Inhibitory Response to CK II Inhibitor Silmitasertib and CDKs Inhibitor Dinaciclib Is Related to Genetic Differences in Pancreatic Ductal Adenocarcinoma Cell Lines

Casein kinase II (CK2) and cyclin-dependent kinases (CDKs) frequently interact within multiple pathways in pancreatic ductal adenocarcinoma (PDAC). Application of CK2- and CDK-inhibitors have been considered as a therapeutic option, but are currently not part of routine chemotherapy regimens. We inv...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ma, Yixuan, Sender, Sina, Sekora, Anett, Kong, Weibo, Bauer, Peter, Ameziane, Najim, Krake, Susann, Radefeldt, Mandy, Al-Ali, Ruslan, Weiss, Frank Ulrich, Lerch, Markus M., Parveen, Alisha, Zechner, Dietmar, Junghanss, Christian, Murua Escobar, Hugo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9031017/ https://www.ncbi.nlm.nih.gov/pubmed/35457227 http://dx.doi.org/10.3390/ijms23084409

Ejemplares similares

The Inhibitory Response to PI3K/AKT Pathway Inhibitors MK-2206 and Buparlisib Is Related to Genetic Differences in Pancreatic Ductal Adenocarcinoma Cell Lines
por: Ma, Yixuan, et al.
Publicado: (2022)

Validation of an LC–MS/MS Method for the Quantification of the CK2 Inhibitor Silmitasertib (CX-4945) in Human Plasma
por: Schwarz, Rico, et al.
Publicado: (2022)

Influence of Casein kinase II inhibitor CX-4945 on BCL6-mediated apoptotic signaling in B-ALL in vitro and in vivo
por: Richter, Anna, et al.
Publicado: (2020)

BTK and PI3K Inhibitors Reveal Synergistic Inhibitory Anti-Tumoral Effects in Canine Diffuse Large B-Cell Lymphoma Cells
por: Kong, Weibo, et al.
Publicado: (2021)

Inhibition of KRAS, MEK and PI3K Demonstrate Synergistic Anti-Tumor Effects in Pancreatic Ductal Adenocarcinoma Cell Lines
por: Ma, Yixuan, et al.
Publicado: (2022)

Precursor B-ALL Cell Lines Differentially Respond to SYK Inhibition by Entospletinib
por: Sender, Sina, et al.
Publicado: (2021)

Establishment and characterization of stable red, far-red (fR) and near infra-red (NIR) transfected canine prostate cancer cell lines
por: Liu, Wen, et al.
Publicado: (2020)

Activation of the Kynurenine Pathway in Human Malignancies Can Be Suppressed by the Cyclin-Dependent Kinase Inhibitor Dinaciclib
por: Riess, Christin, et al.
Publicado: (2020)

Silmitasertib (CX-4945), a Clinically Used CK2-Kinase Inhibitor with Additional Effects on GSK3β and DYRK1A Kinases: A Structural Perspective
por: Grygier, Przemyslaw, et al.
Publicado: (2023)

Pre-therapeutic efficacy of the CDK inhibitor dinaciclib in medulloblastoma cells
por: Buzzetti, Marta, et al.
Publicado: (2021)

CK2 inhibition with silmitasertib promotes methuosis-like cell death associated to catastrophic massive vacuolization of colorectal cancer cells
por: Silva-Pavez, Eduardo, et al.
Publicado: (2019)

Combined Application of Pan-AKT Inhibitor MK-2206 and BCL-2 Antagonist Venetoclax in B-Cell Precursor Acute Lymphoblastic Leukemia
por: Richter, Anna, et al.
Publicado: (2021)

Small Molecule “Silmitasertib” Repurposed as Inhibitor of Transforming Growth Factor Beta 1 for the Development of Therapeutics for Oral Submucous Fibrosis
por: Boreak, Nezar
Publicado: (2021)

Combined Casein Kinase II inhibition and epigenetic modulation in acute B-lymphoblastic leukemia
por: Richter, Anna, et al.
Publicado: (2019)

Evaluation of the Synergistic Potential of Simultaneous Pan- or Isoform-Specific BET and SYK Inhibition in B-Cell Lymphoma: An In Vitro Approach
por: Sender, Sina, et al.
Publicado: (2022)

Combined BCL-2 and PI3K/AKT Pathway Inhibition in KMT2A-Rearranged Acute B-Lymphoblastic Leukemia Cells
por: Holz, Clemens, et al.
Publicado: (2023)

A cyclin-dependent kinase inhibitor, dinaciclib in preclinical treatment models of thyroid cancer
por: Lin, Shu-Fu, et al.
Publicado: (2017)

Dinaciclib as an effective pan-cyclin dependent kinase inhibitor in platinum resistant ovarian cancer
por: Howard, David, et al.
Publicado: (2022)

An Inhibitor’s-Eye View of the ATP-Binding Site of CDKs in Different Regulatory States
por: Echalier, Aude, et al.
Publicado: (2014)

For cdks, one is enough
por: Leslie, Mitch
Publicado: (2007)

Cyclin-dependent kinase inhibitor dinaciclib potently synergizes with cisplatin in preclinical models of ovarian cancer
por: Chen, Xiu-Xiu, et al.
Publicado: (2015)

Cdks set the replication schedule
por: Leslie, Mitch
Publicado: (2010)

Spirooxindol‐1,3‐oxazine Alkaloids: Highly Potent and Selective Antitumor Agents Evolved from Iterative Structure Optimization
por: Eichhorst, Annika, et al.
Publicado: (2022)

Clinical and laboratory studies of the novel cyclin-dependent kinase inhibitor dinaciclib (SCH 727965) in acute leukemias
por: Gojo, Ivana, et al.
Publicado: (2013)

The Anti-Melanoma Activity of Dinaciclib, a Cyclin-Dependent Kinase Inhibitor, Is Dependent on p53 Signaling
por: Desai, Brijal M., et al.
Publicado: (2013)

Novel CDKs inhibitors for the treatment of solid tumour by simultaneously regulating the cell cycle and transcription control
por: Wang, Xin, et al.
Publicado: (2020)

Phosphoproteome Analysis Reveals Differential Mode of Action of Sorafenib in Wildtype and Mutated FLT3 Acute Myeloid Leukemia (AML) Cells
por: Roolf, Catrin, et al.
Publicado: (2017)

Multiple CDK inhibitor dinaciclib suppresses neuroblastoma growth via inhibiting CDK2 and CDK9 activity
por: Chen, Zhenghu, et al.
Publicado: (2016)

Dinaciclib, a cyclin-dependent kinase inhibitor, suppresses cholangiocarcinoma growth by targeting CDK2/5/9
por: Saqub, Hera, et al.
Publicado: (2020)

The Role of CDKs and CDKIs in Murine Development
por: Campbell, Grace Jean, et al.
Publicado: (2020)

Kinetics of Langerhans cell chimerism in the skin of dogs following 2 Gy TBI allogeneic hematopoietic stem cell transplantation
por: Peters, Sabrina, et al.
Publicado: (2016)

Novel Isoquinolinamine and Isoindoloquinazolinone Compounds Exhibit Antiproliferative Activity in Acute Lymphoblastic Leukemia Cells
por: Roolf, Catrin, et al.
Publicado: (2019)

Dinaciclib is a Novel Cyclin Dependent Kinase Inhibitor with Significant Clinical Activity in Relapsed and Refractory Chronic Lymphocytic Leukemia
por: Flynn, Joseph, et al.
Publicado: (2015)

Molecular Basis of Differential Selectivity of Cyclobutyl-Substituted Imidazole Inhibitors against CDKs: Insights for Rational Drug Design
por: Rath, Soumya Lipsa, et al.
Publicado: (2013)

Cdks put Treslin on TopBP1
por: Short, Ben
Publicado: (2011)

Fueling the Cycle: CDKs in Carbon and Energy Metabolism
por: Solaki, Maria, et al.
Publicado: (2018)

Cyclins and CDKs in the regulation of meiosis-specific events
por: Palacios-Blanco, Inés, et al.
Publicado: (2022)

A Simple LC-MS/MS Method for the Quantification of PDA-66 in Human Plasma
por: Schwarz, Rico, et al.
Publicado: (2022)

Effective tumor cell abrogation via Venetoclax-mediated BCL-2 inhibition in KMT2A-rearranged acute B-lymphoblastic leukemia
por: Richter, Anna, et al.
Publicado: (2022)

Flavopiridol (Alvocidib), a Cyclin-dependent Kinases (CDKs) Inhibitor, Found Synergy Effects with Niclosamide in Cutaneous T-cell Lymphoma
por: Zhang, Xu Hannah, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_cq1ai14vdlj5v2bo3odbtp1fbh